<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK546576" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK546576/" /><meta name="ncbi_pagename" content="Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/09/19" /><meta name="citation_author" content="Irene de Boer" /><meta name="citation_author" content="Nadine Pelzer" /><meta name="citation_author" content="Gisela Terwindt" /><meta name="citation_pmid" content="31536185" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK546576/" /><meta name="citation_keywords" content="Cerebroretinal Vasculopathy (CRV)" /><meta name="citation_keywords" content="Hereditary Endotheliopathy, Retinopathy, Nephropathy, and Stroke (HERNS)" /><meta name="citation_keywords" content="Hereditary Systemic Angiopathy (HSA)" /><meta name="citation_keywords" content="Hereditary Vascular Retinopathy (HVR)" /><meta name="citation_keywords" content="Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL)" /><meta name="citation_keywords" content="RVCL-S" /><meta name="citation_keywords" content="RVCL-S" /><meta name="citation_keywords" content="Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL)" /><meta name="citation_keywords" content="Cerebroretinal Vasculopathy (CRV)" /><meta name="citation_keywords" content="Hereditary Vascular Retinopathy (HVR)" /><meta name="citation_keywords" content="Hereditary Systemic Angiopathy (HAS)" /><meta name="citation_keywords" content="Hereditary Endotheliopathy, Retinopathy, Nephropathy, and Stroke (HERNS)" /><meta name="citation_keywords" content="Three prime repair exonuclease 1" /><meta name="citation_keywords" content="TREX1" /><meta name="citation_keywords" content="Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Irene de Boer" /><meta name="DC.Contributor" content="Nadine Pelzer" /><meta name="DC.Contributor" content="Gisela Terwindt" /><meta name="DC.Date" content="2019/09/19" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK546576/" /><meta name="description" content="Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a small-vessel disease that affects highly vascularized tissues including the retina, brain, liver, and kidneys. Age of onset is often between 35 and 50 years. The most common presenting finding is decreased visual acuity and/or visual field defects. Neurologic manifestations may include hemiparesis, facial weakness, aphasia, and hemianopsia. Migraines and seizures are less frequently described. Renal manifestations may include mild-to-moderate increase in serum creatinine and mild proteinuria; progression to end-stage renal disease (ESRD) is uncommon. Hepatic manifestations frequently include mildly elevated levels of alkaline phosphatase and gamma-glutamyltransferase (GGT). Less common findings include psychiatric disorders, hypertension, mild-to-moderate anemia, and Raynaud phenomenon." /><meta name="og:title" content="Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations" /><meta name="og:type" content="book" /><meta name="og:description" content="Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a small-vessel disease that affects highly vascularized tissues including the retina, brain, liver, and kidneys. Age of onset is often between 35 and 50 years. The most common presenting finding is decreased visual acuity and/or visual field defects. Neurologic manifestations may include hemiparesis, facial weakness, aphasia, and hemianopsia. Migraines and seizures are less frequently described. Renal manifestations may include mild-to-moderate increase in serum creatinine and mild proteinuria; progression to end-stage renal disease (ESRD) is uncommon. Hepatic manifestations frequently include mildly elevated levels of alkaline phosphatase and gamma-glutamyltransferase (GGT). Less common findings include psychiatric disorders, hypertension, mild-to-moderate anemia, and Raynaud phenomenon." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK546576/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/rvcl/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK546576/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B43CDE040AB210000000005CB0201.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK546576_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK546576_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/refsum/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/retinoblastoma/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK546576_"><span class="title" itemprop="name">Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Cerebroretinal Vasculopathy (CRV); Hereditary Endotheliopathy, Retinopathy, Nephropathy, and Stroke (HERNS); Hereditary Systemic Angiopathy (HSA); Hereditary Vascular Retinopathy (HVR); Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL); RVCL-S</div><p class="contrib-group"><span itemprop="author">Irene de Boer</span>, MD, <span itemprop="author">Nadine Pelzer</span>, MD, PhD, and <span itemprop="author">Gisela Terwindt</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK546576_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK546576_ai__"><div class="contrib half_rhythm"><span itemprop="author">Irene de Boer</span>, MD<div class="affiliation small">Leiden University Medical Center<br />Leiden, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.cmul@reobedi" class="oemail">ln.cmul@reobedi</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Nadine Pelzer</span>, MD, PhD<div class="affiliation small">Leiden University Medical Center<br />Leiden, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.cmul@rezlep.n" class="oemail">ln.cmul@rezlep.n</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Gisela Terwindt</span>, MD, PhD<div class="affiliation small">Leiden University Medical Center<br />Leiden, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.cmul@tdniwret.m.g" class="oemail">ln.cmul@tdniwret.m.g</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 19, 2019</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="rvcl.Summary" itemprop="description"><h2 id="_rvcl_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>R</i>etinal <i>v</i>asculopathy with <i>c</i>erebral <i>l</i>eukoencephalopathy and <i>s</i>ystemic manifestations (RVCL-S) is a small-vessel disease that affects highly vascularized tissues including the retina, brain, liver, and kidneys. Age of onset is often between 35 and 50 years. The most common presenting finding is decreased visual acuity and/or visual field defects. Neurologic manifestations may include hemiparesis, facial weakness, aphasia, and hemianopsia. Migraines and seizures are less frequently described. Renal manifestations may include mild-to-moderate increase in serum creatinine and mild proteinuria; progression to end-stage renal disease (ESRD) is uncommon. Hepatic manifestations frequently include mildly elevated levels of alkaline phosphatase and gamma-glutamyltransferase (GGT). Less common findings include psychiatric disorders, hypertension, mild-to-moderate anemia, and Raynaud phenomenon.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of RVCL-S is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive findings and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TREX1</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Retinal vasculopathy may be treated with laser therapy, which may also prevent and slow the progression of visual impairment; macular edema may respond to bevacizumab; ESRD may require renal replacement therapy (including renal transplantation); corticosteroid therapy may be considered for those with cerebral vasogenic edema; standard treatment for glaucoma, hypertension, migraine headaches, seizure disorders, hypothyroidism, anemia, Raynaud phenomenon, and psychiatric disorders.</p><p><i>Surveillance</i>: Ophthalmologic evaluation, blood pressure assessment, renal function tests (serum creatinine, BUN, and urinalysis to include creatinine and protein content), liver function tests (AST, ALT, alkaline phosphatase, GGT, serum albumin), TSH and free T4, and complete blood count annually starting in the fourth decade or as appropriate based on symptoms; annual assessment of cognition and psychiatric manifestations.</p><p><i>Agents/circumstances to avoid</i>: Intravenous tissue-type plasminogen activator therapy for acute ischemic stroke is not warranted, as there is no proof that neurologic manifestations are caused by occluded large blood vessels and the risk of complications is assumed to be higher in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to evaluate the genetic status of apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>RVCL-S is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Most individuals diagnosed with RVCL-S have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. However, disease onset and severity vary considerably even within the same family. The offspring of an individual with RVCL-S are at a 50% risk of inheriting the <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. If the pathogenic variant in the family is known, prenatal testing for pregnancies at increased risk for RVCL-S and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> are possible; however, such testing for adult-onset disorders is uncommon.</p></div></div><div id="rvcl.Diagnosis"><h2 id="_rvcl_Diagnosis_">Diagnosis</h2><p>There are no consensus clinical diagnostic criteria for retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S).</p><div id="rvcl.Suggestive_Findings"><h3>Suggestive Findings</h3><p>RVCL-S <b>should be suspected</b> in individuals with the following findings [<a class="bk_pop" href="#rvcl.REF.stam.2016.2909">Stam et al 2016</a>, <a class="bk_pop" href="#rvcl.REF.pelzer.2019.317">Pelzer et al 2019</a>].</p><p><b>Major features</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Vascular retinopathy typically manifesting as decreased visual acuity and/or visual field defects</div></li><li class="half_rhythm"><div class="half_rhythm">Focal and/or global brain dysfunction and brain MRI abnormalities</div><ul><li class="half_rhythm"><div>Focal neurologic signs can include but are not limited to hemiparesis, facial weakness, aphasia, and hemianopsia.</div></li><li class="half_rhythm"><div>Global brain dysfunction may manifest as progressive cognitive impairment.</div></li><li class="half_rhythm"><div>Brain MRI abnormalities are restricted to the white matter (see Clinical Characteristics, <a href="#rvcl.Neurologic_Features">Neurologic Features</a>).</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Family history of middle-age onset of disease manifestations consistent with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance pattern</div><div class="half_rhythm">Note: Absence of a known family history of similarly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals does not preclude the diagnosis.</div></li></ul><p><b>Supportive features</b></p><ul><li class="half_rhythm"><div>Calcifications on brain CT scan, typically not present in healthy controls</div></li><li class="half_rhythm"><div>Nonspecific MRI white matter lesions that occur more frequently than expected given the age of the individual</div></li><li class="half_rhythm"><div>Microvascular liver disease, manifested by modest elevations of alkaline phosphatase and gamma-glutamyltransferase</div></li><li class="half_rhythm"><div>Microvascular kidney disease, typically manifested by a mild-to-moderate increase in serum creatinine or by proteinuria</div></li></ul><p><b>Likely associated features</b></p><ul><li class="half_rhythm"><div>Anemia consistent with blood loss and/or chronic disease (typically normocytic and normochromic)</div></li><li class="half_rhythm"><div>Microscopic gastrointestinal bleeding</div></li><li class="half_rhythm"><div>Hypertension</div></li><li class="half_rhythm"><div>Migraine with or without aura</div></li><li class="half_rhythm"><div>Raynaud phenomenon (typically mild)</div></li><li class="half_rhythm"><div>Subclinical hypothyroidism</div></li></ul></div><div id="rvcl.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of RVCL-S <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive findings and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TREX1</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK546576/table/rvcl.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figrvclTmoleculargenetictestingusedin" rid-ob="figobrvclTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>TREX1</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>TREX1</i>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>TREX1</i> and other genes of interest (see <a href="#rvcl.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p>Note: At the Leiden University Medical Center, a panel of genes is used to screen for pathogenic variants that cause cerebral angiopathies and adult-onset leukoencephalopathies. New pathogenic variants that cause these disorders continue to be discovered; click <a href="https://www.lumc.nl/org/klinische-genetica/patientenzorg/aanvragen-laboratoriumdiagnostiek/?setlanguage=English&#x00026;setcountry=en" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a> for more information.</p><div id="rvcl.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK546576/table/rvcl.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rvcl.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rvcl.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_rvcl.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_rvcl.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic<br />Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_rvcl.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TREX1</i></td><td headers="hd_h_rvcl.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_rvcl.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Estimated &#x0003e;99%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_rvcl.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_rvcl.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rvcl.TF.1.1"><p class="no_margin">See <a href="/books/NBK546576/#rvcl.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="rvcl.TF.1.2"><p class="no_margin">See <a href="#rvcl.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="rvcl.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="rvcl.TF.1.4"><p class="no_margin">The identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TREX1</i> is required for the diagnosis RVCL-S. The proportion of individuals with suggestive features of RVCL-S who do not have an identifiable heterozygous pathogenic variant in <i>TREX1</i> has not been systematically studied.</p></div></dd><dt>5. </dt><dd><div id="rvcl.TF.1.5"><p class="no_margin">To date, all pathogenic variants in <i>TREX1</i> that cause RVCL-S have been frameshift variants in the region encoding the C terminus of the protein.</p></div></dd><dt>6. </dt><dd><div id="rvcl.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="rvcl.TF.1.7"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd></dl></div></div></div></div></div><div id="rvcl.Clinical_Characteristics"><h2 id="_rvcl_Clinical_Characteristics_">Clinical Characteristics</h2><div id="rvcl.Clinical_Description"><h3>Clinical Description</h3><p>Clinical information about RVCL-S is summarized from the following reports of individuals with molecularly confirmed RVCL-S: <a class="bk_pop" href="#rvcl.REF.storimans.1991.73">Storimans et al [1991]</a>, <a class="bk_pop" href="#rvcl.REF.terwindt.1998.303">Terwindt et al [1998]</a>, <a class="bk_pop" href="#rvcl.REF.cohn.2005.181">Cohn et al [2005]</a>, <a class="bk_pop" href="#rvcl.REF.richards.2007.1068">Richards et al [2007]</a>, <a class="bk_pop" href="#rvcl.REF.winkler.2008.77">Winkler et al [2008]</a>, <a class="bk_pop" href="#rvcl.REF.mateen.2010.1211">Mateen et al [2010]</a>, <a class="bk_pop" href="#rvcl.REF.gruver.2011.20">Gruver et al [2011]</a>, <a class="bk_pop" href="#rvcl.REF.schuh.2014.e55">Schuh et al [2014]</a>, <a class="bk_pop" href="#rvcl.REF.dhamija.2015.1633">Dhamija et al [2015]</a>, <a class="bk_pop" href="#rvcl.REF.difrancesco.2015.323">DiFrancesco et al [2015]</a>, <a class="bk_pop" href="#rvcl.REF.stam.2016.2909">Stam et al [2016]</a>, <a class="bk_pop" href="#rvcl.REF.vodopivec.2016.507">Vodopivec et al [2016]</a>, <a class="bk_pop" href="#rvcl.REF.carradalliere.2017.113">Carra-Dalliere et al [2017]</a>, <a class="bk_pop" href="#rvcl.REF.hardy.2017">Hardy et al [2017]</a>, and <a class="bk_pop" href="#rvcl.REF.pelzer.2019.317">Pelzer et al [2019]</a>. The numerators and denominators in this section are derived from the study by <a class="bk_pop" href="#rvcl.REF.stam.2016.2909">Stam et al [2016]</a>, which included 11 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> families and is the largest study to date on RVCL-S.</p><p>RVCL-S is a small-vessel disease that systemically affects various highly vascularized organs. Affected individuals develop retinal vasculopathy and neurologic symptoms, in addition to other systemic manifestations including impaired liver and renal function.</p><p>Clinical presentation is variable; onset is often between ages 35 and 50 years, with a mean age at clinical diagnosis of 42.9 years (SD &#x000b1;8.3, range 25-61 years). Life expectancy is decreased; the average age of death is 53.1 years (SD &#x000b1;9.6, range 32-72). Cause of death is frequently pneumonia or sepsis in the setting of general debilitation. For clinical course see <a class="figpopup" href="/books/NBK546576/figure/rvcl.F1/?report=objectonly" target="object" rid-figpopup="figrvclF1" rid-ob="figobrvclF1">Figure 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figrvclF1" co-legend-rid="figlgndrvclF1"><a href="/books/NBK546576/figure/rvcl.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figrvclF1" rid-ob="figobrvclF1"><img class="small-thumb" src="/books/NBK546576/bin/rvcl-Image001.gif" src-large="/books/NBK546576/bin/rvcl-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndrvclF1"><h4 id="rvcl.F1"><a href="/books/NBK546576/figure/rvcl.F1/?report=objectonly" target="object" rid-ob="figobrvclF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Clinical course of RVCL-S Adapted from Pelzer et al [2019]</p></div></div><div id="rvcl.Ophthalmologic_Features"><h4>Ophthalmologic Features</h4><p><b>Symptoms</b></p><ul><li class="half_rhythm"><div>Symptoms caused by retinal vasculopathy are the most common presenting finding in individuals with RVCL-S but can also develop later in the disease course.</div></li><li class="half_rhythm"><div>Affected individuals often notice decreased visual acuity and/or visual field defects. A gradual worsening often occurs and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals can become legally blind.</div></li></ul><p><b>Signs</b></p><ul><li class="half_rhythm"><div>All individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TREX1</i> will develop vascular retinopathy at some point.</div></li><li class="half_rhythm"><div>The retinopathy is characterized in the early stages by telangiectasias, microaneurysms, and cotton wool spots.</div></li><li class="half_rhythm"><div>In later stages perifoveal capillary obliterations and neovascularizations appear.</div></li><li class="half_rhythm"><div>Macular edema and neovascular glaucoma may develop as a complication of vascular retinopathy.</div></li></ul></div><div id="rvcl.Neurologic_Features"><h4>Neurologic Features</h4><p><b>Symptoms</b></p><ul><li class="half_rhythm"><div><b>Focal neurologic symptoms</b> were reported in 40/72 individuals. These symptoms occurred more frequently in those with retinal vasculopathy and/or brain lesions (40/59). Manifestations include but are not limited to hemiparesis, facial weakness, aphasia, and hemianopsia.</div></li><li class="half_rhythm"><div><b>Cognitive impairment</b> has been described in 32/57 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with retinal vasculopathy and/or brain lesions. This ratio is higher (21/28) in those with more disease symptoms, implying a progressive decline in cognition. Apathy, irritability, and difficulties with memory and judgment have also been reported.</div></li><li class="half_rhythm"><div><b>Migraine</b> occurred in 24/41 individuals in whom other manifestations of the disease (retinal vasculopathy and/or brain lesions) were present. Of 16 deceased individuals, 12 had a history of migraine at some point in their life; further clinical details are unavailable.</div></li><li class="half_rhythm"><div><b>Seizures</b> occurred in 9/66 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Generalized as well as partial sensomotoric seizures have been described.</div></li></ul><p><b>Signs on neuroimaging.</b> Three types of lesions have been observed frequently on brain MRI scans:</p><ul><li class="half_rhythm"><div><b>Focal, non-enhancing T<sub>2</sub>-hyperintense lesions</b> scattered throughout the periventricular and deep white matter (at an age when nonspecific age-related white matter hyperintensities are infrequent)</div></li><li class="half_rhythm"><div><b>Punctate T<sub>2</sub>-hyperintense white matter lesions</b> with nodular enhancement</div></li><li class="half_rhythm"><div><b>Hyperintense mass lesions on T<sub>2</sub> and hypointense lesions on T<sub>1</sub>-weighted images,</b> enhanced with gadolinium contrast, and often surrounded by extensive edema. Hemorrhages are rarely reported. Occasionally, restricted diffusion, most often centrally, is observed and is referred to as a "pseudotumor." These lesions:</div><ul><li class="half_rhythm"><div>Have been reported in 36/51 individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TREX1</i>, most often in later stages of the disease;</div></li><li class="half_rhythm"><div>Are most frequently localized in the frontoparietal lobe but are occasionally found in other regions;</div></li><li class="half_rhythm"><div>Often lead to displacement of adjacent structures and sulci effacement;</div></li><li class="half_rhythm"><div>Can increase in size, remain stable, or diminish;</div></li><li class="half_rhythm"><div>Are associated with calcifications on CT scan.</div></li></ul></li></ul></div><div id="rvcl.Renal_Disease"><h4>Renal Disease</h4><p>Renal disease has been demonstrated in 22/44 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. It is typically characterized by a mild-to-moderate increase in serum creatinine and mild proteinuria but may be severe (stage IV kidney disease) and fatal in some families. While the progression of the renal disease of RVCL-S requires further study, in most cases the renal manifestations are progressive; however, there is tremendous variability in the rate of renal decline.</p></div><div id="rvcl.Liver_Disease"><h4>Liver Disease</h4><p>Liver disease was present in 28/40 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and usually manifests as mildly elevated levels of alkaline phosphatase and gamma-glutamyltransferase (GGT).</p></div><div id="rvcl.Hypothyroidism"><h4>Hypothyroidism</h4><p>Subclinical hypothyroidism was found to be part of the disease course in a recent cross-sectional study. Of the 19 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals older than age 40 years, seven had subclinical hypothyroidism.</p></div><div id="rvcl.Psychiatric_Symptoms"><h4>Psychiatric Symptoms</h4><p>Psychiatric manifestations were present in 26/62 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and may include depression, psychosis, anxiety, and other psychiatric problems.</p></div><div id="rvcl.Other"><h4>Other</h4><p>Additional findings may include the following:</p><ul><li class="half_rhythm"><div>Hypertension (present in 30/52 individuals)</div></li><li class="half_rhythm"><div>Mild-to-moderate anemia that is typically normocytic and normochromic</div></li><li class="half_rhythm"><div>Microscopic gastrointestinal bleeding resulting in anemia (present in 25/34 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals)</div></li><li class="half_rhythm"><div>Raynaud phenomenon, which is typically mild (present in approximately 31/73 individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TREX1</i>)</div></li><li class="half_rhythm"><div>Avascular necrosis of the femoral head (2 individuals)</div></li><li class="half_rhythm"><div>(Hypertensive) cardiomyopathy (3 individuals)</div></li><li class="half_rhythm"><div>Macular skin rash and punctate skin lesions (3 individuals)</div></li></ul></div><div id="rvcl.Pathology"><h4>Pathology</h4><p>Histologic abnormalities have been demonstrated in all organs involved in RVCL-S, including the following.</p><p><b>Retina</b></p><ul><li class="half_rhythm"><div>Scattered microinfarcts</div></li><li class="half_rhythm"><div>Thickened hyalinized retinal arterial walls</div></li><li class="half_rhythm"><div>Focal areas of disruption of the ganglion cell layer and inner nuclear layer</div></li></ul><p><b>Brain</b></p><ul><li class="half_rhythm"><div>Multiple &#x02013; often confluent &#x02013; foci of ischemic necrosis of white matter</div></li></ul><ul><li class="half_rhythm"><div>Vasculopathy: vessel wall thickening and luminal stenosis; telangiectasias</div></li><li class="half_rhythm"><div>A modest chronic inflammatory cell infiltrate in some individuals</div></li><li class="half_rhythm"><div>Focal calcifications and reactive astrocytosis</div></li><li class="half_rhythm"><div>Myelin loss</div></li></ul><p><b>Kidney</b></p><ul><li class="half_rhythm"><div>Renal arteriolosclerosis</div></li><li class="half_rhythm"><div>Focal or diffuse glomerulosclerosis</div></li></ul><p><b>Liver</b></p><ul><li class="half_rhythm"><div>Nodular regenerative hyperplasia</div></li><li class="half_rhythm"><div>Micro- and macrovesicular steatosis</div></li><li class="half_rhythm"><div>Periportal inflammation</div></li><li class="half_rhythm"><div>Bridging and portal fibrosis</div></li></ul></div></div><div id="rvcl.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>To date, all pathogenic variants have been frameshift variants in the region of <i>TREX1</i> encoding the carboxyl terminus of TREX1 (see <a href="#rvcl.Molecular_Genetics">Molecular Genetics</a>).</p><p>To date no <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been observed.</p></div><div id="rvcl.Penetrance"><h3>Penetrance</h3><p>Penetrance of RVCL-S is age dependent; however, it is thought that all individuals with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic <i>TREX1</i> variant will develop features of this condition if they live long enough.</p></div><div id="rvcl.Nomenclature"><h3>Nomenclature</h3><p>Previous descriptions of families with cerebroretinal vasculopathy (CRV); hereditary vascular retinopathy (HRV); hereditary endotheliopathy, retinopathy, nephropathy, and stroke (HERNS); hereditary systemic angiopathy (HSA); and retinal vasculopathy with cerebral leukodystrophy (RVCL) represent early reports of RVCL-S.</p></div><div id="rvcl.Prevalence"><h3>Prevalence</h3><p>Currently, fewer than 25 families with RVCL-S are known. However, RVCL-S is most likely underdiagnosed because physicians are generally unfamiliar with the disorder. For example, in the Netherlands alone three unrelated families have been identified because of increased awareness of this condition. The widespread availability of <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> techniques likely also contribute to increased recognition of RVCL-S.</p></div></div><div id="rvcl.Genetically_Related_Allelic_Disorde"><h2 id="_rvcl_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><a class="figpopup" href="/books/NBK546576/table/rvcl.T.allelic_disorders/?report=objectonly" target="object" rid-figpopup="figrvclTallelicdisorders" rid-ob="figobrvclTallelicdisorders">Table 2</a> includes other phenotypes caused by pathogenic variants in <i>TREX1</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> associated with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S).</p><div id="rvcl.T.allelic_disorders" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Allelic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK546576/table/rvcl.T.allelic_disorders/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rvcl.T.allelic_disorders_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rvcl.T.allelic_disorders_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_rvcl.T.allelic_disorders_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_rvcl.T.allelic_disorders_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TREX1</i></td><td headers="hd_h_rvcl.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ags/">Aicardi-Gouti&#x000e8;res syndrome</a>&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_rvcl.T.allelic_disorders_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Chilblain lupus (OMIM <a href="https://omim.org/entry/610448" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610448</a>)&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_rvcl.T.allelic_disorders_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Susceptibility to systemic lupus erythematosus (OMIM <a href="https://omim.org/entry/152700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">152700</a>)&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_rvcl.T.allelic_disorders_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Scleroderma (systemic sclerosis) [<a class="bk_pop" href="#rvcl.REF.hughes.2017.77">Hughes et al 2017</a>]</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rvcl.TF.2.1"><p class="no_margin">See hyperlinked <i>GeneReview</i>, OMIM <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> entry, or cited reference for more information.</p></div></dd><dt>2. </dt><dd><div id="rvcl.TF.2.2"><p class="no_margin">Pathogenic variants typically affect one of three exonuclease domains of <i>TREX1</i> and lead to a reduced or ablated exonuclease activity [<a class="bk_pop" href="#rvcl.REF.lehtinen.2008.31649">Lehtinen et al 2008</a>].</p></div></dd></dl></div></div></div><p>In addition, two individuals with <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants were found to have early-onset cerebrovascular disease, without the presence of typical RVCL-S lesions on MRI brain or typical RVCL-S features even though they were older than age 40 years [<a class="bk_pop" href="#rvcl.REF.pelzer.2013.2188">Pelzer et al 2013</a>].</p></div><div id="rvcl.Differential_Diagnosis"><h2 id="_rvcl_Differential_Diagnosis_">Differential Diagnosis</h2><p>Due to the systemic nature of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S), the differential diagnosis is quite broad. Following are differential diagnoses specifically for the characteristic <a href="#rvcl.Focal_andor_Global_Brain_Dysfunctio">brain findings</a> and <a href="#rvcl.Vascular_Retinopathy">vascular retinopathy</a> seen in RVCL-S. For other inherited disorders with phenotypic similarities see <a class="figpopup" href="/books/NBK546576/table/rvcl.T.inherited_disorders_to_consider_i/?report=objectonly" target="object" rid-figpopup="figrvclTinheriteddisorderstoconsideri" rid-ob="figobrvclTinheriteddisorderstoconsideri">Table 3</a>.</p><div id="rvcl.Focal_andor_Global_Brain_Dysfunctio"><h3>Focal and/or Global Brain Dysfunction / MRI Brain Abnormalities</h3><p>Focal and/or global brain dysfunction and MRI brain abnormalities (intracerebral mass lesions and white matter abnormalities) seen in RVCL-S can be similar to intracranial neoplasm, multiple sclerosis, multi-infarct dementia, and central nervous system vasculitis. In these disorders other organs are usually not <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Moreover, these conditions do not typically follow an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance pattern.</p><ul><li class="half_rhythm"><div>In sarcoidosis and systemic lupus erythematosus (SLE) (see <a class="figpopup" href="/books/NBK546576/table/rvcl.T.inherited_disorders_to_consider_i/?report=objectonly" target="object" rid-figpopup="figrvclTinheriteddisorderstoconsideri" rid-ob="figobrvclTinheriteddisorderstoconsideri">Table 3</a>) there can be focal and/or global brain dysfunction as well as involvement of multiple organs, as is seen in RVCL-S.</div></li><li class="half_rhythm"><div>With sarcoidosis, however, there is frequent involvement of the lungs and skin. No lesions in the lungs have been described in individuals with RVCL-S and skin lesions are not frequently reported [<a class="bk_pop" href="#rvcl.REF.hardy.2017">Hardy et al 2017</a>].</div></li></ul></div><div id="rvcl.Vascular_Retinopathy"><h3>Vascular Retinopathy</h3><p>Vascular retinopathy can occur as a long-term complication of diabetes mellitus and hypertension:</p><ul><li class="half_rhythm"><div>As the vascular retinopathy in RVCL-S is usually observed at a relatively young age (retinopathy has been found in the third decade of life) it is unlikely to be a complication of hypertension or diabetes mellitus, even in those with RVCL-S who have co-occurrence of hypertension or diabetes.</div></li><li class="half_rhythm"><div>Vascular retinopathy can also be caused by systemic lupus erythematosus, sarcoidosis, and ophthalmologic infections (which are outside of the scope of this <i>GeneReview</i>).</div></li><li class="half_rhythm"><div>In Susac syndrome, vascular retinopathy and encephalopathy are part of the symptomatology, as is hearing loss, but hearing loss is very rare in RVCL-S. The pattern of white matter lesions seen on MRI may also help to distinguish the two conditions.</div></li></ul><div id="rvcl.T.inherited_disorders_to_consider_i" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Inherited Disorders to Consider in the Differential Diagnosis of RVCL-S</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK546576/table/rvcl.T.inherited_disorders_to_consider_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rvcl.T.inherited_disorders_to_consider_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" style="text-align:left;vertical-align:middle;">Differential<br />Diagnosis<br />Disorder</th><th id="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of the Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4" id="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/RVCL-S</th><th headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4" id="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from RVCL-S</th></tr></thead><tbody><tr><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cadasil/">CADASIL</a></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NOTCH3</i></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Focal neurologic symptoms</div></li><li class="half_rhythm"><div>Progressive cognitive decline</div></li><li class="half_rhythm"><div>Migraine</div></li><li class="half_rhythm"><div>Mood disturbances</div></li><li class="half_rhythm"><div>Apathy</div></li><li class="half_rhythm"><div>White matter lesions on brain imaging</div></li><li class="half_rhythm"><div>Positive family history</div></li></ul>
</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Clinical involvement limited to the brain</div></li><li class="half_rhythm"><div>The pattern of white matter lesions on brain imaging differs from that in RVCL-S.</div></li></ul>
</td></tr><tr><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CARASAL</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CTSA</i></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ischemic stroke</div></li><li class="half_rhythm"><div>Progressive cognitive decline</div></li><li class="half_rhythm"><div>Extended white matter lesions on brain imaging</div></li><li class="half_rhythm"><div>Hypertension</div></li></ul>
</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemorrhagic strokes occur frequently in CARASAL.</td></tr><tr><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/carasil/">CARASIL</a></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HTRA1</i></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Stepwise deterioration in brain functions</div></li><li class="half_rhythm"><div>Progressive cognitive decline</div></li><li class="half_rhythm"><div>Extended white matter lesions on brain imaging</div></li><li class="half_rhythm"><div>Positive family history</div></li></ul>
</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Spasticity in lower extremities, spondylosis deformans &#x00026; alopecia</div></li><li class="half_rhythm"><div>AR inheritance</div></li></ul>
</td></tr><tr><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/fabry/">Fabry disease</a></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GLA</i></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Focal neurologic complaints</div></li><li class="half_rhythm"><div>Nephropathy</div></li><li class="half_rhythm"><div>Positive family history</div></li></ul>
</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Angiokeratomas, hypohidrosis, &#x00026; corneal opacity</div></li><li class="half_rhythm"><div>Onset usually in childhood or adolescence</div></li><li class="half_rhythm"><div>XL inheritance; <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females can be asymptomatic w/normal life span.</div></li></ul>
</td></tr><tr><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/nf1/">Neurofibromatosis 1</a></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NF1</i></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Focal neurologic symptoms w/mass lesions on brain imaging</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Migraine</div></li><li class="half_rhythm"><div>Positive family history</div></li></ul>
</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Caf&#x000e9; au lait macules, neurofibroma, plexiform neurofibroma, freckling in axillary or inguinal regions, optic glioma, Lisch noduli, &#x00026; distinctive osseous lesions</div></li><li class="half_rhythm"><div>Pattern of lesions on brain imaging differs from that seen in RVCL-S.</div></li></ul>
</td></tr><tr><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Systemic lupus erythematosus<br />(OMIM <a href="https://omim.org/entry/152700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">152700</a>)</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CTLA4</i><br /><i>DNASE1</i><br /><i>FCGR2A</i><br /><i>FCGR2B</i><br /><i>PTPN22</i><br /><i>TREX1</i></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD&#x000a0;<sup>1</sup></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Nephropathy</div></li><li class="half_rhythm"><div>Anemia</div></li><li class="half_rhythm"><div>Retinopathy</div></li><li class="half_rhythm"><div>Mood disorders</div></li><li class="half_rhythm"><div>Cognitive complaints</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Liver disease</div></li></ul>
</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Often no genetic <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found</div></li><li class="half_rhythm"><div>Features of vasculitis can occur, specifically cutaneous abnormalities, oral or nasal ulcers, alopecia, &#x00026; arthritis.</div></li><li class="half_rhythm"><div>Often associated w/&#x02191; ANAs, anti-dsDNA; anti-Smith antibodies &#x00026;/or antiphospholipid antibodies (anticardiolipin immunoglobin or lupus anticoagulant)</div></li></ul>
</td></tr><tr><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/tuberous-sclerosis/">Tuberous sclerosis complex</a></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TSC1</i><br /><i>TSC2</i></td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Multisystem disorder involving brain, kidney, &#x00026; eye</div></li><li class="half_rhythm"><div>Focal neurologic symptoms</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>Mass lesions on brain imaging</div></li><li class="half_rhythm"><div>Positive family history</div></li></ul>
</td><td headers="hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_1_4 hd_h_rvcl.T.inherited_disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Formation of hamartomas &#x00026; skin&#x00026; lung lesions</div></li><li class="half_rhythm"><div>Many patients are diagnosed as children, but it is not uncommon for adults to be diagnosed.</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; ANAs = antinuclear antibodies; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; CADASIL = cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CARASAL = cathepsin A&#x02013;related arteriopathy with strokes and leukoencephalopathy; CARASIL = cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy; dsDNA = double-stranded DNA; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="rvcl.TF.3.1"><p class="no_margin">Most frequently, no genetic cause is identified.</p></div></dd></dl></div></div></div></div></div><div id="rvcl.Management"><h2 id="_rvcl_Management_">Management</h2><div id="rvcl.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations, the evaluations summarized in <a class="figpopup" href="/books/NBK546576/table/rvcl.T.recommended_evaluations_following/?report=objectonly" target="object" rid-figpopup="figrvclTrecommendedevaluationsfollowing" rid-ob="figobrvclTrecommendedevaluationsfollowing">Table 4</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="rvcl.T.recommended_evaluations_following" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with RVCL-S</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK546576/table/rvcl.T.recommended_evaluations_following/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rvcl.T.recommended_evaluations_following_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologic evaluation</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for signs of retinopathy, macular edema, &#x00026; glaucoma.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blood pressure</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for hypertension.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Renal</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Renal function tests&#x000a0;<sup>1</sup></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to nephrologist for those w/significant renal insufficiency &#x00026;/or hypertension.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hepatology</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Liver enzymes&#x000a0;<sup>2</sup> &#x00026; serum albumin</div></li><li class="half_rhythm"><div>Consideration of serum lactate dehydrogenase levels, coagulation studies, &#x00026; bilirubin concentration</div></li></ul>
</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to gastroenterologist for those w/significantly altered liver enzymes or &#x02193; liver function.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess cognitive function.</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to neurologist &#x00026;/or a neuropsychological evaluation.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for signs &#x00026; symptoms of migraines.</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to neurologist.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">EEG if seizures are suspected</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for focal neurologic complaints.</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refer to neurologist, if present.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Endocrinologic</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thyroid function&#x000a0;<sup>3</sup></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refer to endocrinologist, if clinically significant</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hematologic</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complete blood count</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for anemia; consider referral to gastroenterologist for possible occult GI bleeding.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Rheumatologic</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for signs &#x00026; symptoms of Raynaud phenomenon.</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for psychiatric symptoms.&#x000a0;<sup>4</sup></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider psychiatric consultation.</td></tr><tr><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_rvcl.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rvcl.TF.4.1"><p class="no_margin">Serum creatinine, BUN, and urinalysis (to include creatinine and protein content)</p></div></dd><dt>2. </dt><dd><div id="rvcl.TF.4.2"><p class="no_margin">Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, gamma-glutamyltransferase (GGT)</p></div></dd><dt>3. </dt><dd><div id="rvcl.TF.4.3"><p class="no_margin">TSH and free T4</p></div></dd><dt>4. </dt><dd><div id="rvcl.TF.4.4"><p class="no_margin">Findings may include depression, psychosis, anxiety, or other psychiatric diagnoses.</p></div></dd></dl></div></div></div><p>It is crucial that unnecessary diagnostic tests not be undertaken. Biopsies of the brain, kidney, or liver are not required in individuals with RVCL-S and do not appear to provide additional prognostic or treatment information.</p></div><div id="rvcl.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><a class="figpopup" href="/books/NBK546576/table/rvcl.T.treatment_of_manifestations_in_in/?report=objectonly" target="object" rid-figpopup="figrvclTtreatmentofmanifestationsinin" rid-ob="figobrvclTtreatmentofmanifestationsinin">Table 5</a> summarizes treatment for the manifestations of an individual diagnosed with RVCL-S.</p><div id="rvcl.T.treatment_of_manifestations_in_in" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Retinal Vasculopathy with RVCL-S</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK546576/table/rvcl.T.treatment_of_manifestations_in_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rvcl.T.treatment_of_manifestations_in_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/Concern</th><th id="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Visual impairment</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Retinal laser therapy</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Can prevent &#x00026; slow down progression of retinal involvement that causes visual impairment</td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Macular edema</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bevacizumab</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Elevated eye pressure /</b><br /><b>Glaucoma</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hypertension</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May prevent further damage to involved organs</td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Renal insufficiency</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment of hypertension</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Refer to nephrologist.</td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Renal replacement therapy (incl transplantation) may be considered in severe cases for those w/end-stage renal disease.</td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Liver function abnormalities</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">There is no treatment for liver function abnormalities.</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor to prevent complications associated w/liver fibrosis &#x00026; to exclude other causes.&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cerebral vascular</b><br /><b>edema</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider corticosteroid therapy.&#x000a0;<sup>2</sup></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May reduce cerebral vasogenic edema but does not appear to treat the underlying lesion</td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Migraine</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizure disorder</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment w/antiepileptic drugs</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refer to neurologist.</td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hypothyroidism</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Thyroid replacement therapy</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Anemia</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intravenous iron therapy (&#x00026; in rare cases blood transfusion) may be necessary.</td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Raynaud phenomenon</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric concerns</b></td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rvcl.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refer to psychiatrist or neuropsychologist.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rvcl.TF.5.1"><p class="no_margin">When not properly monitored, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are frequently given incorrect diagnoses and often receive advice to stop drinking alcohol or stop their medication, while this is not required.</p></div></dd><dt>2. </dt><dd><div id="rvcl.TF.5.2"><p class="no_margin">Intravenous methylprednisolone followed by an oral corticosteroid treatment</p></div></dd></dl></div></div></div></div><div id="rvcl.Surveillance"><h3>Surveillance</h3><p>There are currently no consensus guidelines for monitoring individuals with RVCL-S. However, close monitoring is recommended. The frequency of monitoring depends on the manifestations and rate of disease progression (see <a class="figpopup" href="/books/NBK546576/table/rvcl.T.recommended_surveillance_for_indi/?report=objectonly" target="object" rid-figpopup="figrvclTrecommendedsurveillanceforindi" rid-ob="figobrvclTrecommendedsurveillanceforindi">Table 6</a>).</p><div id="rvcl.T.recommended_surveillance_for_indi" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with RVCL-S</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK546576/table/rvcl.T.recommended_surveillance_for_indi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rvcl.T.recommended_surveillance_for_indi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency (Minimum)</th></tr></thead><tbody><tr><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologic evaluation</td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;">Annually starting in 4th decade or as appropriate based on symptoms</td></tr><tr><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blood pressure evaluation</td></tr><tr><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Renal</b></td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Renal function tests&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Endocrinologic</b></td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TSH and free T4</td></tr><tr><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hematologic</b></td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complete blood count</td></tr><tr><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hepatology</b></td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver enzymes&#x000a0;<sup>2</sup> &#x00026; serum albumin</td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually starting in the 4th decade</td></tr><tr><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment of cognition</td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Annually or as appropriate based on symptoms starting after diagnosis</td></tr><tr><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric</b></td><td headers="hd_h_rvcl.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment for psychiatric symptoms</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rvcl.TF.6.1"><p class="no_margin">Serum creatinine, BUN, and urinalysis (to include creatinine and protein content)</p></div></dd><dt>2. </dt><dd><div id="rvcl.TF.6.2"><p class="no_margin">Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, gamma-glutamyltransferase (GGT)</p></div></dd></dl></div></div></div></div><div id="rvcl.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Although there is no evidence, the authors would advise against intravenous tissue-type plasminogen activator (IV tPA) for acute ischemic stroke. There is to date no proof that the neurologic manifestations are caused by occluded large blood vessels (RVCL-S is a small vessel disease), and the risk of complications of such treatment (e.g., a secondary hemorrhage) is assumed to be higher in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="rvcl.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate the genetic status of apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment that could benefit eyesight and prevent secondary damage due to hypertension. Furthermore, clarification of the genetic status of at-risk relatives could prevent unnecessary diagnostic tests (e.g., liver/kidney/brain biopsies).</p><p>See <a href="#rvcl.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="rvcl.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Currently, a pilot study for treating RVCL-S with aclarubicin has been started. For details, see <a href="https://clinicaltrials.gov/ct2/show/NCT02723448?term=NCT02723448&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials NCT02723448</a>.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="rvcl.Genetic_Counseling"><h2 id="_rvcl_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="rvcl.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="rvcl.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with RVCL-S have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. However, there is large variability within families in disease onset and severity.</div></li><li class="half_rhythm"><div>Some individuals diagnosed with RVCL-S have the disorder as the result of a <i>de novo TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#rvcl.REF.difrancesco.2015.323">DiFrancesco et al 2015</a>]. Because <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) have not been evaluated sufficiently to determine if the pathogenic variant occurred <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>, the proportion of RVCL-S caused by a <i>de novo</i> pathogenic variant is unknown.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with RVCL-S may appear to be negative because of failure to recognize the disorder in family members (RVLC-S can be misdiagnosed as multiple sclerosis, multi-infarct / frontal lobe dementia, or other organ dysfunction), early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#rvcl.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li><li class="half_rhythm"><div>The absence of clinical manifestations in parents whose genetic status is unknown cannot be used to predict risk to sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> or late onset in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with RVCL-S has a 50% chance of inheriting the <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p></div><div id="rvcl.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#rvcl.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="rvcl.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the <i>TREX1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="rvcl.Resources"><h2 id="_rvcl_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>RVCL Association</b></div><div>Netherlands</div><div><a href="http://www.rvclresearch.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rvclresearch.org</a></div></li><li class="half_rhythm"><div><b>RVCLresearch.org</b></div><div><a href="http://www.rvclresearch.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rvclresearch.org</a></div></li><li class="half_rhythm"><div><b>European Leukodystrophy Association (ELA)</b></div><div>2, rue Mi-les-Vignes</div><div>B.P. 61024</div><div>Laxou Cedex 54521</div><div>France</div><div><b>Phone:</b> 03833093 34</div><div><b>Fax:</b> 03833000 68</div><div><b>Email:</b> ela@ela-asso.com</div><div><a href="http://www.ela-asso.com" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ela-asso.com</a></div></li><li class="half_rhythm"><div><b>Retina International</b></div><div>Retina Suisse</div><div>Ausstellungsstrasse 36</div><div> Zurich CH-8005</div><div>Switzerland</div><div><b>Phone:</b> +41 (0) 44 444 1077</div><div><b>Fax:</b> +41 (0) 44 444 1070</div><div><b>Email:</b> christina.fasser@retina-international.org</div><div><a href="http://www.retina-international.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.retina-international.org</a></div></li><li class="half_rhythm"><div><b>United Leukodystrophy Foundation (ULF)</b></div><div>224 North Second Street</div><div>Suite 2</div><div>DeKalb IL 60115</div><div><b>Phone:</b> 800-728-5483 (toll-free); 815-748-3211</div><div><b>Fax:</b> 815-748-0844</div><div><b>Email:</b> office@ulf.org</div><div><a href="http://www.ulf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ulf.org</a></div></li></ul></div><div id="rvcl.Molecular_Genetics"><h2 id="_rvcl_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="rvcl.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK546576/table/rvcl.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rvcl.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_rvcl.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_rvcl.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_rvcl.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_rvcl.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_rvcl.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_rvcl.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_rvcl.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/11277" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TREX1</i></a></td><td headers="hd_b_rvcl.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=11277" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3p21<wbr style="display:inline-block"></wbr>​.31</a></td><td headers="hd_b_rvcl.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Three prime repair exonuclease 1</td><td headers="hd_b_rvcl.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/TREX1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Three prime repair exonuclease 1 (TREX1) @ LOVD</a></td><td headers="hd_b_rvcl.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TREX1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TREX1</a></td><td headers="hd_b_rvcl.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TREX1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TREX1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="rvcl.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="rvcl.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations (<a href="/omim/192315,606609" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK546576/table/rvcl.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rvcl.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/192315" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">192315</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VASCULOPATHY, RETINAL, WITH CEREBRAL LEUKODYSTROPHY; RVCL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606609" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606609</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3-PRIME @REPAIR EXONUCLEASE 1; TREX1</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The <i>TREX1</i> transcript <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_033629.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_033629.5</a> has two exons, the first being a short noncoding <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>. Alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> results in alternate transcripts. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, transcript, and protein information see <a href="/books/NBK546576/#rvcl.molgen.TA">Table A</a>.</p><p><b>Pathogenic variants.</b> In RVCL-S, the sequence alterations in <i>TREX1</i> are frameshift variants typically resulting in a truncated C terminus of the TREX1 protein [<a class="bk_pop" href="#rvcl.REF.richards.2007.1068">Richards et al 2007</a>, <a class="bk_pop" href="#rvcl.REF.schuh.2014.e55">Schuh et al 2014</a>, <a class="bk_pop" href="#rvcl.REF.dhamija.2015.1633">Dhamija et al 2015</a>, <a class="bk_pop" href="#rvcl.REF.stam.2016.2909">Stam et al 2016</a>, <a class="bk_pop" href="#rvcl.REF.vodopivec.2016.507">Vodopivec et al 2016</a>, <a class="bk_pop" href="#rvcl.REF.carradalliere.2017.113">Carra-Dalliere et al 2017</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> TREX1 is a major 3'-5' exonuclease in mammals and is responsible for the removal of nucleoside monophosphates from the 3' ends of DNA [<a class="bk_pop" href="#rvcl.REF.mazur.1999.19655">Mazur &#x00026; Perrino 1999</a>]. It has a high affinity for single-stranded DNA [<a class="bk_pop" href="#rvcl.REF.h_ss.1999.3868">H&#x000f6;ss et al 1999</a>]. TREX1 (<a href="https://www.ncbi.nlm.nih.gov/protein/NP_338599.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_338599.1</a>) contains 314 amino acid residues, which are highly conserved among species [<a class="bk_pop" href="#rvcl.REF.leekirsch.2007.1065">Lee-Kirsch et al 2007</a>]. TREX1 has three exonuclease domains in the N terminus and a C-terminal <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, which is required for its localization to the endoplasmic reticulum [<a class="bk_pop" href="#rvcl.REF.mazur.1999.19655">Mazur &#x00026; Perrino 1999</a>, <a class="bk_pop" href="#rvcl.REF.richards.2007.1068">Richards et al 2007</a>, <a class="bk_pop" href="#rvcl.REF.difrancesco.2015.323">DiFrancesco et al 2015</a>, <a class="bk_pop" href="#rvcl.REF.hasan.2015.463">Hasan et al 2015</a>]. TREX1 also appears to be involved in the regulation of oligosaccharyltransferase activity [<a class="bk_pop" href="#rvcl.REF.hasan.2015.463">Hasan et al 2015</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Heterozygous frameshift pathogenic variants in the C terminus of TREX1 cause RVCL-S [<a class="bk_pop" href="#rvcl.REF.richards.2007.1068">Richards et al 2007</a>, <a class="bk_pop" href="#rvcl.REF.stam.2016.2909">Stam et al 2016</a>]. These are predicted to result in a truncated TREX1 protein. The exonuclease function of the protein is not <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but its subcellular localization is altered [<a class="bk_pop" href="#rvcl.REF.richards.2007.1068">Richards et al 2007</a>, <a class="bk_pop" href="#rvcl.REF.difrancesco.2015.323">DiFrancesco et al 2015</a>, <a class="bk_pop" href="#rvcl.REF.hasan.2015.463">Hasan et al 2015</a>]. Recently it was demonstrated that the C terminus of TREX1 has a role in the regulation of the oligosaccharlytransferase complex located on the endoplasmic reticulum [<a class="bk_pop" href="#rvcl.REF.hasan.2015.463">Hasan et al 2015</a>]. In lymphoblasts of individuals with RVCL-S this led to an increased free glycan release that could potentially cause immune activation [<a class="bk_pop" href="#rvcl.REF.hasan.2015.463">Hasan et al 2015</a>]. In light of these findings, it is especially interesting that a distinct antibody profile was demonstrated in a mouse model for RVCL-S [<a class="bk_pop" href="#rvcl.REF.sakai.2017.13">Sakai et al 2017</a>]. A remaining question is how pathogenic variants in the C terminus of TREX1 cause the multisystem vasculopathy seen in individuals with RVCL-S [<a class="bk_pop" href="#rvcl.REF.stam.2009.1006">Stam et al 2009</a>].</p></div><div id="rvcl.References"><h2 id="_rvcl_References_">References</h2><div id="rvcl.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.carradalliere.2017.113">Carra-Dalliere C, Ayrignac X, Prieto-Morin C, Girard P, Tournier-Lasserve E, Labauge P. TREX1 mutation in leukodystrophy with calcifications and persistent gadolinium-enhancement. <span><span class="ref-journal">Eur Neurol. </span>2017;<span class="ref-vol">77</span>:113–4.</span> [<a href="/pubmed/28013302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28013302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.cohn.2005.181">Cohn AC, Kotschet K, Veitch A, Delatycki MB, McCombe MF. Novel ophthalmological features in hereditary endotheliopathy with retinopathy, nephropathy and stroke syndrome. <span><span class="ref-journal">Clin Exp Ophthalmol. </span>2005;<span class="ref-vol">33</span>:181–3.</span> [<a href="/pubmed/15807828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15807828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.dhamija.2015.1633">Dhamija R, Schiff D, Lopes MB, Jen JC, Lin DD, Worrall BB. Evolution of brain lesions in a patient with TREX1 cerebroretinal vasculopathy. <span><span class="ref-journal">Neurology. </span>2015;<span class="ref-vol">85</span>:1633–4.</span> [<a href="/pubmed/26527794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26527794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.difrancesco.2015.323">DiFrancesco JC, Novara F, Zuffardi O, Forlino A, Gioia R, Cossu F, Bolognesi M, Andreoni S, Saracchi E, Frigeni B, Stellato T, Tolnay M, Winkler DT, Remida P, Isimbaldi G, Ferrarese C. TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. <span><span class="ref-journal">Neurol Sci. </span>2015;<span class="ref-vol">36</span>:323–30.</span> [<a href="/pubmed/25213617" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25213617</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.gruver.2011.20">Gruver AM, Schoenfield L, Coleman JF, Hajj-Ali R, Rodriguez ER, Tan CD. Novel ophthalmic pathology in an autopsy case of autosomal dominant retinal vasculopathy with cerebral leukodystrophy. <span><span class="ref-journal">J Neuroophthalmol. </span>2011;<span class="ref-vol">31</span>:20–4.</span> [<a href="/pubmed/21131853" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21131853</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.hardy.2017">Hardy TA, Young S, Sy JS, Colley AF, Terwindt GM, Ferrari MD, Hayes MW, Hodgkinson S. Tumefactive lesions in retinal vasculopathy with cerebral leucoencephalopathy and systemic manifestations (RVCL-S): a role for neuroinflammation? <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2017.</span> Epub ahead of print. [<a href="/pubmed/28794152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28794152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.hasan.2015.463">Hasan M, Fermaintt CS, Gao N, Sakai T, Miyazaki T, Jiang S, Li QZ, Atkinson JP, Morse HC 3rd, Lehrman MA, Yan N. Cytosolic nuclease TREX1 regulates oligosaccharyltransferase activity independent of nuclease activity to suppress immune activation. <span><span class="ref-journal">Immunity. </span>2015;<span class="ref-vol">43</span>:463–74.</span> [<a href="/pmc/articles/PMC4575271/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4575271</span></a>] [<a href="/pubmed/26320659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26320659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.h_ss.1999.3868">H&#x000f6;ss M, Robins P, Naven TJ, Pappin DJ, Sgouros J, Lindahl T. A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. <span><span class="ref-journal">EMBO J. </span>1999;<span class="ref-vol">18</span>:3868–75.</span> [<a href="/pmc/articles/PMC1171463/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1171463</span></a>] [<a href="/pubmed/10393201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10393201</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.hughes.2017.77">Hughes M, Little J, Herrick AL, Pushpakom S, Byers H, Worthington J, Newman WG. A synonymous variant in TREX1 is associated with systemic sclerosis and severe digital ischaemia. <span><span class="ref-journal">Scand J Rheumatol. </span>2017;<span class="ref-vol">46</span>:77–8.</span> [<a href="/pubmed/27574969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27574969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.leekirsch.2007.1065">Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, de Silva U, Bailey SL, Witte T, Vyse TJ, Kere J, Pfeiffer C, Harvey S, Wong A, Koskenmies S, Hummel O, Rohde K, Schmidt RE, Dominiczak AF, Gahr M, Hollis T, Perrino FW, Lieberman J, H&#x000fc;bner N. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. <span><span class="ref-journal">Nat Genet. </span>2007;<span class="ref-vol">39</span>:1065–7.</span> [<a href="/pubmed/17660818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17660818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.lehtinen.2008.31649">Lehtinen DA, Harvey S, Mulcahy MJ, Hollis T, Perrino FW. The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. <span><span class="ref-journal">J Biol Chem. </span>2008;<span class="ref-vol">283</span>:31649–56.</span> [<a href="/pmc/articles/PMC2581595/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2581595</span></a>] [<a href="/pubmed/18805785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18805785</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.mateen.2010.1211">Mateen FJ, Krecke K, Younge BR, Ford AL, Shaikh A, Kothari PH, Atkinson JP. Evolution of a tumor-like lesion in cerebroretinal vasculopathy and TREX1 mutation. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">75</span>:1211–3.</span> [<a href="/pmc/articles/PMC3013489/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3013489</span></a>] [<a href="/pubmed/20876473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20876473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.mazur.1999.19655">Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3'--&#x0003e;5' exonucleases. <span><span class="ref-journal">J Biol Chem. </span>1999;<span class="ref-vol">274</span>:19655–60.</span> [<a href="/pubmed/10391904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10391904</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.pelzer.2019.317">Pelzer N, Hoogeveen ES, Haan J, Bunnik R, Poot CC, van Zwet EW, Inderson A, Fogteloo AJ, Reinders MEJ, Middelkoop HAM, Kruit MC, van den Maagdenberg AMJM, Ferrari MD, Terwindt GM. Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease. <span><span class="ref-journal">J Intern Med. </span>2019;<span class="ref-vol">285</span>:317–32.</span> [<a href="/pubmed/30411414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30411414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.pelzer.2013.2188">Pelzer N, de Vries B, Boon EM, Kruit MC, Haan J, Ferrari MD, van den Maagdenberg AM, Terwindt GM. Heterozygous TREX1 mutations in early-onset cerebrovascular disease. <span><span class="ref-journal">J Neurol. </span>2013;<span class="ref-vol">260</span>:2188–90.</span> [<a href="/pubmed/23881107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23881107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.richards.2007.1068">Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D, Liszewski MK, Barilla-Labarca ML, Terwindt GM, Kasai Y, McLellan M, Grand MG, Vanmolkot KR, de Vries B, Wan J, Kane MJ, Mamsa H, Sch&#x000e4;fer R, Stam AH, Haan J, de Jong PT, Storimans CW, van Schooneveld MJ, Oosterhuis JA, Gschwendter A, Dichgans M, Kotschet KE, Hodgkinson S, Hardy TA, Delatycki MB, Hajj-Ali RA, Kothari PH, Nelson SF, Frants RR, Baloh RW, Ferrari MD, Atkinson JP. C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. <span><span class="ref-journal">Nature genetics. </span>2007;<span class="ref-vol">39</span>:1068–70.</span> [<a href="/pubmed/17660820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17660820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.sakai.2017.13">Sakai T, Miyazaki T, Shin DM, Kim YS, Qi CF, Fariss R, Munasinghe J, Wang H, Kovalchuk AL, Kothari PH, Fermaintt CS, Atkinson JP, Perrino FW, Yan N, Morse HC 3rd. DNase-active TREX1 frame-shift mutants induce serologic autoimmunity in mice. <span><span class="ref-journal">J Autoimmun. </span>2017;<span class="ref-vol">81</span>:13–23.</span> [<a href="/pmc/articles/PMC5558601/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5558601</span></a>] [<a href="/pubmed/28325644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28325644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.schuh.2014.e55">Schuh E, Ertl-Wagner B, Lohse P, Wolf W, Mann JF, Lee-Kirsch MA, Hohlfeld R, K&#x000fc;mpfel T. Multiple sclerosis-like lesions and type I interferon signature in a patient with RVCL. <span><span class="ref-journal">Neurol Neuroimmunol Neuroinflamm. </span>2014;<span class="ref-vol">2</span>:e55</span> [<a href="/pmc/articles/PMC4277301/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4277301</span></a>] [<a href="/pubmed/25566545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25566545</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.stam.2009.1006">Stam AH, Haan J, van den Maagdenberg AM, Ferrari MD, Terwindt GM. Migraine and genetic and acquired vasculopathies. <span><span class="ref-journal">Cephalalgia. </span>2009;<span class="ref-vol">29</span>:1006–17.</span> [<a href="/pubmed/19689610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19689610</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.stam.2016.2909">Stam AH, Kothari PH, Shaikh A, Gschwendter A, Jen JC, Hodgkinson S, Hardy TA, Hayes M, Kempster PA, Kotschet KE, Bajema IM, van Duinen SG, Maat-Schieman ML, de Jong PT, de Smet MD, de Wolff-Rouendaal D, Dijkman G, Pelzer N, Kolar GR, Schmidt RE, Lacey J, Joseph D, Fintak DR, Grand MG, Brunt EM, Liapis H, Hajj-Ali RA, Kruit MC, van Buchem MA, Dichgans M, Frants RR, van den Maagdenberg AM, Haan J, Baloh RW, Atkinson JP, Terwindt GM, Ferrari MD. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. <span><span class="ref-journal">Brain. </span>2016;<span class="ref-vol">139</span>:2909–22.</span> [<a href="/pmc/articles/PMC5091044/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5091044</span></a>] [<a href="/pubmed/27604306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27604306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.storimans.1991.73">Storimans CW, Van Schooneveld MJ, Oosterhuis JA, Bos PJ. A new autosomal dominant vascular retinopathy syndrome. <span><span class="ref-journal">Eur J Ophthalmol. </span>1991;<span class="ref-vol">1</span>:73–8.</span> [<a href="/pubmed/1821204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1821204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.terwindt.1998.303">Terwindt GM, Haan J, Ophoff RA, Groenen SM, Storimans CW, Lanser JB, Roos RA, Bleeker-Wagemakers EM, Frants RR, Ferrari MD. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. <span><span class="ref-journal">Brain. </span>1998;<span class="ref-vol">121</span>:303–16.</span> [<a href="/pubmed/9549508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9549508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.vodopivec.2016.507">Vodopivec I, Oakley DH, Perugino CA, Venna N, Hedley-Whyte ET, Stone JH. A. 44-year-old man with eye, kidney, and brain dysfunction. <span><span class="ref-journal">Ann Neurol. </span>2016;<span class="ref-vol">79</span>:507–19.</span> [<a href="/pmc/articles/PMC4858325/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4858325</span></a>] [<a href="/pubmed/26691497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26691497</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rvcl.REF.winkler.2008.77">Winkler DT, Lyrer P, Probst A, Devys D, Haufschild T, Haller S, Willi N, Mihatsch MJ, Steck AJ, Tolnay M. Hereditary systemic angiopathy (HSA) with cerebral calcifications, retinopathy, progressive nephropathy, and hepatopathy. <span><span class="ref-journal">J Neurol. </span>2008;<span class="ref-vol">255</span>:77–88.</span> [<a href="/pubmed/18204807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18204807</span></a>]</div></li></ul></div></div><div id="rvcl.Chapter_Notes"><h2 id="_rvcl_Chapter_Notes_">Chapter Notes</h2><div id="rvcl.Author_Notes"><h3>Author Notes</h3><p><b>Leiden University Medical Center web pages</b> (in Dutch)</p><p><a href="https://www.lumc.nl/patientenzorg/ziektebeelden/cha/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RVCL-S patient information</a><br /><a href="https://www.lumc.nl/org/hoofdpijn-onderzoek/onderzoek/RVCL/?setlanguage=Dutch&#x00026;setcountry=nl" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RVCL research</a></p><p>The Leiden University Medical Center has expertise in the diagnosis and treatment of RVCL-S and other cerebral hereditary angiopathies (CHA). As part of a consortium we were involved in finding the <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> &#x02013; <i>TREX1</i> &#x02013; responsible for RVCL-S. We aim to study RVCL-S disease pathology through our collaboration with world-renowned scientists and our integrated clinical, radiologic, molecular, and biological approach with this unique patient group and our transgenic mouse model, and aim to include new exciting research opportunities such as brain-on-chip development.</p></div><div id="rvcl.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>19 September 2019 (ma) Review posted live</div></li><li class="half_rhythm"><div>15 November 2017 (gt) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK546576</span><span class="label">PMID: <a href="/pubmed/31536185" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31536185</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/refsum/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/retinoblastoma/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK546576&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK546576/?report=reader">PubReader</a></li><li><a href="/books/NBK546576/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK546576" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK546576" style="display:none" title="Cite this Page"><div class="bk_tt">de Boer I, Pelzer N, Terwindt G. Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations. 2019 Sep 19. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK546576/pdf/Bookshelf_NBK546576.pdf">PDF version of this page</a> (556K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#rvcl.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#rvcl.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#rvcl.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#rvcl.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#rvcl.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#rvcl.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#rvcl.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#rvcl.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#rvcl.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#rvcl.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#rvcl.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=11277[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TREX1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4840038" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4840038" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4840038" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4840038" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25323666" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Neuropathology and genetics of cerebroretinal vasculopathies.</a><span class="source">[Brain Pathol. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Neuropathology and genetics of cerebroretinal vasculopathies.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kolar GR, Kothari PH, Khanlou N, Jen JC, Schmidt RE, Vinters HV. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Brain Pathol. 2014 Sep; 24(5):510-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25213617" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy.</a><span class="source">[Neurol Sci. 2015]</span><div class="brieflinkpop offscreen_noflow">TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">DiFrancesco JC, Novara F, Zuffardi O, Forlino A, Gioia R, Cossu F, Bolognesi M, Andreoni S, Saracchi E, Frigeni B, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurol Sci. 2015 Feb; 36(2):323-30. Epub 2014 Sep 12.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31805844" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Increased Mortality and Vascular Phenotype in a Knock-In Mouse Model of Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations.</a><span class="source">[Stroke. 2020]</span><div class="brieflinkpop offscreen_noflow">Increased Mortality and Vascular Phenotype in a Knock-In Mouse Model of Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mulder IA, Rubio-Beltran E, Ibrahimi K, Dzyubachyk O, Khmelinskii A, Hoehn M, Terwindt GM, Wermer MJH, MaassenVanDenBrink A, van den Maagdenberg AMJM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Stroke. 2020 Jan; 51(1):300-307. Epub 2019 Dec 6.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301768" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">COL4A1</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">COL4A1</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Plaisier E, Ronco P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301444" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alström Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alström Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Paisey RB, Steeds R, Barrett T, Williams D, Geberhiwot T, Gunay-Aygun M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31536185" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31536185" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041822dd21425a253abc93">Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestatio...</a><div class="ralinkpop offscreen_noflow">Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:17:06-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B43CDE040AB210000000005CB0201&amp;ncbi_session=CE8B43CDE0418211_1483SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK546576%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK546576&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK546576/&amp;ncbi_pagename=Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic Manifestations - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B43CDE0418211_1483SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>